(Q36192806)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16014000%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

review article

1 reference

title

The pharmacogenetics of coumarin therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16014000%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16014000%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

author name string

Howard L McLeod

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16014000%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Charles Eby

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16014000%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Brian F Gage

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16014000%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

publication date

1 July 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16014000%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16014000%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

volume

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16014000%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16014000%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

page(s)

503-513

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16014000%20AND%20SRC:MED&resulttype=core&format=json

Genetic mechanisms for hypersensitivity and resistance to the anticoagulant Warfarin

30 December 2019

cites work

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.503

The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.503

A randomized trial comparing 5-mg and 10-mg warfarin loading doses.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.503

Comparison of 10-mg and 5-mg warfarin initiation nomograms together with low-molecular-weight heparin for outpatient treatment of acute venous thromboembolism. A randomized, double-blind, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.503

Warfarin: metabolism and mode of action

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.503

Identification of the gene for vitamin K epoxide reductase

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.503

Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.503

Cytochrome P4502C9: an enzyme of major importance in human drug metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.503

Implications of cytochrome P450 2C9 polymorphism on warfarin metabolism and dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.503

Pharmacogenetics of warfarin elimination and its clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.503

CYP2C9 and oral anticoagulation therapy with acenocoumarol and warfarin: similarities yet differences

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.503

Anticoagulant activity of the enantiomers of acenocoumarol

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.503

Identification of cytochromes P450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.503

Effects of CYP2C9 polymorphisms on the pharmacokinetics of R- and S-phenprocoumon in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.503

Crystal structure of human cytochrome P450 2C9 with bound warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.503

Polymorphism in CYP2C9 as a non-critical factor of warfarin dosage adjustment in Korean patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.503

Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.503

Genetic polymorphisms and functional characterization of the 5'-flanking region of the human CYP2C9 gene: in vitro and in vivo studies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.503

5'-Flanking region polymorphisms of CYP2C9 and their relationship to S-warfarin metabolism in white and Japanese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.503

CYP2C9 exon 4 mutations and warfarin dose phenotype in Asians

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.503

Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.503

A common genetic basis for idiosyncratic toxicity of warfarin and phenytoin.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.503

Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.503

Acenocoumarol pharmacokinetics in relation to cytochrome P450 2C9 genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.503

Catalytic activity of three variants (Ile, Leu, and Thr) at amino acid residue 359 in human CYP2C9 gene and simultaneous detection using single-strand conformation polymorphism analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.503

Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.503

Differential effects of 2C9*3 and 2C9*2 variants of cytochrome P-450 CYP2C9 on sensitivity to acenocoumarol

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.503

Cytochrome P450 2C9 polymorphisms (CYP2C9) and warfarin maintenance dose in elderly patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.503

Warfarin and acenocoumarol dose requirements according to CYP2C9 genotyping in North-Italian patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.503

Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.503

Acenocoumarol stabilization is delayed in CYP2C93 carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.503

The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.503

Determination of bleeding risk using genetic markers in patients taking phenprocoumon

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.503

Risk factors for intracranial hemorrhage in outpatients taking warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.503

Oral anticoagulation and risk of death: a medical record linkage study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.503

Optimal intensity of oral anticoagulant therapy after myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.503

Optimal oral anticoagulant therapy in patients with mechanical heart valves.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.503

Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.503

Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.503

Aging and the anticoagulant response to warfarin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.503

Interindividual variability in sensitivity to warfarin--Nature or nurture?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.503

Age as a determinant of sensitivity to warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.503

Population pharmacokinetics of racemic warfarin in adult patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.503

Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.503

Racial background is a determinant of average warfarin dose required to maintain the INR between 2.0 and 3.0.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.503

Factors affecting the maintenance dose of warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.503

Patient-specific factors predictive of warfarin dosage requirements

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.503

Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.503

Hereditary warfarin resistance. Investigation of a rare phenomenon.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.503

A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.503

The inhibitory effect of calumenin on the vitamin K-dependent gamma-carboxylation system. Characterization of the system in normal and warfarin-resistant rats

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.503

Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gamma-glutamyl carboxylase) gene variants with warfarin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.503

A mutation in the propeptide of Factor IX leads to warfarin sensitivity by a novel mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.503

Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.503

Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.503

Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.503

Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.503

CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.503

Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.503

Frequency of cytochrome P450 2C9 mutant alleles in a Korean population

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.503

Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4'-hydroxylation activities in livers of Japanese and Caucasian populations

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.6.5.503

21 January 2018

Identifiers

DOI

10.2217/14622416.6.5.503

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16014000%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

1 reference